Duchenne Muscular Dystrophy and Rare Disease Patient Access to Treatments Newborn Screening for Rare Diseases
2026 · 1st Quarter (Jan 1 - Mar 31)
SAREPTA THERAPEUTICS, INC.
Filed by SAREPTA THERAPEUTICS, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- Not reported
- Expenses
- $270,000.00
- Registrant
- SAREPTA THERAPEUTICS, INC.
- Filing UUID
- 180006ef-c60d-44c9-918a-ea75812aa42a
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Scientific Innovation in Healthcare Gene Therapies Artificial Intelligence and Data Governance
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.